menu
    • menu
    [{"orgOrder":0,"company":"Radiopharm Theranostics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Radiolabelled Compounds","year":"2024","type":"Inapplicable","leadProduct":"177-Lu RAD202","moa":"HER2","graph1":"Oncology","graph2":"IND Enabling","graph3":"Radiopharm Theranostics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Radiopharm Theranostics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Radiopharm Theranostics \/ Inapplicable"},{"orgOrder":0,"company":"Radiopharm Theranostics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Radiolabelled Compounds","year":"2025","type":"Inapplicable","leadProduct":"177-Lu RAD202","moa":"HER2","graph1":"Oncology","graph2":"Phase I","graph3":"Radiopharm Theranostics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Radiopharm Theranostics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Radiopharm Theranostics \/ Inapplicable"},{"orgOrder":0,"company":"Radiopharm Theranostics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Radiolabelled Compounds","year":"2023","type":"Inapplicable","leadProduct":"68-Ga Trivehexin","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Radiopharm Theranostics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Radiopharm Theranostics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Radiopharm Theranostics \/ Inapplicable"},{"orgOrder":0,"company":"Radiopharm Theranostics","sponsor":"Lantheus Holding","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Radiolabelled Compounds","year":"2024","type":"Private Placement","leadProduct":"68-Ga Trivehexin","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Radiopharm Theranostics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Radiopharm Theranostics \/ Lantheus Holding","highestDevelopmentStatusID":"6","companyTruncated":"Radiopharm Theranostics \/ Lantheus Holding"},{"orgOrder":0,"company":"Radiopharm Theranostics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"RAD204","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Radiopharm Theranostics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Radiopharm Theranostics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Radiopharm Theranostics \/ Inapplicable"},{"orgOrder":0,"company":"Radiopharm Theranostics","sponsor":"SHINE Technologies","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"n.c.a. 177-Lu","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Radiopharm Theranostics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Radiopharm Theranostics \/ SHINE Technologies","highestDevelopmentStatusID":"4","companyTruncated":"Radiopharm Theranostics \/ SHINE Technologies"},{"orgOrder":0,"company":"Radiopharm Theranostics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Radiolabelled Compounds","year":"2025","type":"Inapplicable","leadProduct":"177-Lu RAD204","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I","graph3":"Radiopharm Theranostics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Radiopharm Theranostics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Radiopharm Theranostics \/ Inapplicable"},{"orgOrder":0,"company":"Radiopharm Theranostics","sponsor":"Isotope Technologies Munich","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Radiolabelled Compounds","year":"2025","type":"Agreement","leadProduct":"177-Lu RAD204","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I","graph3":"Radiopharm Theranostics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Radiopharm Theranostics \/ Radiopharm Theranostics","highestDevelopmentStatusID":"6","companyTruncated":"Radiopharm Theranostics \/ Radiopharm Theranostics"}]

    Find Clinical Drug Pipeline Developments & Deals by Radiopharm Theranostics

    Menu

    Radiopharm Theranostics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Radiopharm Theranostics

                            Australia arrow
                            STLE Annual Meeting
                            Not Confirmed

                            Radiopharm Theranostics

                            Australia arrow
                            STLE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 177-Lu RAD204

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Recipient : Isotope Technologies Munich

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            ITM and Radiopharm Sign Supply Agreement for n.c.a. Lutetium-177

                            Details : Radiopharm will use ITM’s n.c.a. 177Lu across its clinical pipeline, including in key programs such as RAD 204, RAD 202, and RV01, for the treatment of solid tumors.

                            Product Name : 177-Lu RAD204

                            Product Type : Radiolabelled Compounds

                            Upfront Cash : Undisclosed

                            May 19, 2025

                            Lead Product(s) : 177-Lu RAD204

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Recipient : Isotope Technologies Munich

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Radiopharm Theranostics

                            Australia arrow
                            STLE Annual Meeting
                            Not Confirmed

                            Radiopharm Theranostics

                            Australia arrow
                            STLE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 177-Lu RAD204

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Radiopharm Speeds 177Lu-RAD204 Trial After DSMC Gives Positive Go-Ahead

                            Details : 177Lu-RAD204 is a PD-L1 modulator radiolabelled antibody, which is being evaluated for the treatment of PD-L1 positive advanced cancers.

                            Product Name : 177-Lu RAD204

                            Product Type : Radiolabelled Compounds

                            Upfront Cash : Inapplicable

                            May 12, 2025

                            Lead Product(s) : 177-Lu RAD204

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Radiopharm Theranostics

                            Australia arrow
                            STLE Annual Meeting
                            Not Confirmed

                            Radiopharm Theranostics

                            Australia arrow
                            STLE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 177-Lu RAD202

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            New RAD202 Data Confirms Positive Tumor Uptake and Favorable Biodistribution

                            Details : RAD202 is a proprietary single domain antibody that targets HER2. It is being investigated for the treatment of HER2-positive solid tumors.

                            Product Name : 177-Lu RAD202

                            Product Type : Radiolabelled Compounds

                            Upfront Cash : Inapplicable

                            March 17, 2025

                            Lead Product(s) : 177-Lu RAD202

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Radiopharm Theranostics

                            Australia arrow
                            STLE Annual Meeting
                            Not Confirmed

                            Radiopharm Theranostics

                            Australia arrow
                            STLE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 177-Lu RAD202

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            RAD 202 Receives Approval to Start Phase 1 Therapeutic Trial

                            Details : 177Lu-RAD202 is an HER2 inhibitor, antibody radiopharmaceutical candiidate, which is being evaluated for the treatment of HER2-expressing solid tumors.

                            Product Name : 177Lu-RAD202

                            Product Type : Radiolabelled Compounds

                            Upfront Cash : Inapplicable

                            December 20, 2024

                            Lead Product(s) : 177-Lu RAD202

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Radiopharm Theranostics

                            Australia arrow
                            STLE Annual Meeting
                            Not Confirmed

                            Radiopharm Theranostics

                            Australia arrow
                            STLE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 68-Ga Trivehexin

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Lantheus Holding

                            Deal Size : $18.0 million

                            Deal Type : Private Placement

                            DEALS_DEV arrow-down

                            Radiopharm Receives Strategic Investment for up to A$18 million

                            Details : The company will use the net proceeds of Lantheus’ investment for drug advancement RAD301 ([68Ga]-Trivehexin), which is being evaluated for treating pancreatic neoplasms.

                            Product Name : RAD301

                            Product Type : Radiolabelled Compounds

                            Upfront Cash : Undisclosed

                            June 19, 2024

                            Lead Product(s) : 68-Ga Trivehexin

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Lantheus Holding

                            Deal Size : $18.0 million

                            Deal Type : Private Placement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Radiopharm Theranostics

                            Australia arrow
                            STLE Annual Meeting
                            Not Confirmed

                            Radiopharm Theranostics

                            Australia arrow
                            STLE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RAD204

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            RAD Receives Approval for Phase 1 Therapeutic Study of PDL1-nanobody in Non-Small Cell Lung Cancer

                            Details : RAD204, which targets PDL1-positive NSCLC, which used technology underpinning the trial is Radiopharm’s proprietary nanobody from its NanoMab platform.

                            Product Name : RAD204

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            September 10, 2023

                            Lead Product(s) : RAD204

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Radiopharm Theranostics

                            Australia arrow
                            STLE Annual Meeting
                            Not Confirmed

                            Radiopharm Theranostics

                            Australia arrow
                            STLE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 68-Ga Trivehexin

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Radiopharm Theranostics Receives FDA Orphan Drug Designation for Trivehexin (RAD 301) in Pancreatic Cancer

                            Details : RAD301 (68Ga-Trivehexin) is a proprietary peptide-based molecule that targets avf6-integrin, a cellular marker for tumor invasion and metastatic growth, the expression of which correlates with decreased survival in several carcinomas.

                            Product Name : RAD301

                            Product Type : Radiolabelled Compounds

                            Upfront Cash : Inapplicable

                            September 05, 2023

                            Lead Product(s) : 68-Ga Trivehexin

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Radiopharm Theranostics

                            Australia arrow
                            STLE Annual Meeting
                            Not Confirmed

                            Radiopharm Theranostics

                            Australia arrow
                            STLE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : n.c.a. 177-Lu

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : SHINE Technologies

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Radiopharm Theranostics and SHINE Technologies Announce Clinical Supply Agreement for Cancer-Fighting Medical ...

                            Details : The isotope will be used by Radiopharm in the development of its clinical pipeline of diagnostic and therapeutic radiopharmaceutical products including RAD206. Lu-177 is an important isotope utilized in multiple programs across Radiopharm’s portfolio.

                            Product Name : RAD206

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            September 19, 2022

                            Lead Product(s) : n.c.a. 177-Lu

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : SHINE Technologies

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth